Recent Updates
Recently added Catalysts
ARVN Positive Sentiment Score: 75/100

Arvinas to Participate in Upcoming Investor Conferences

Tuesday, March 4, 2025 2 min read
Key Takeaway: Arvinas, Inc. will take part in three upcoming investor conferences: the Leerink Partners Global Healthcare Conference, the Jefferies Biotech on the Beach Summit, and the Barclays Global Healthcare Conference. Company executives including CFO Andrew Saik and CBO Randy Teel will lead discussions and presentations. Arvinas is working on several drug candidates aimed at conditions like ER+/HER2- breast cancer and neurodegenerative disorders, showcasing their commitment to innovative therapeutic solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arvinas is participating in three significant investor conferences, raising visibility.
  • Management will engage in fireside chats, indicating transparency and proactivity.
  • The company is progressing multiple investigational drugs through clinical development.

Full Press Release Details

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:
Leerink Partners Global Healthcare Conference 2025 on Tuesday, March 11. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
Jefferies Biotech on the Beach Summit on Wednesday, March 12. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in one-on-one meetings.
Barclays 27th Annual Global Healthcare Conference on Thursday, March 13. Andrew Saik, Chief Financial Officer, and Randy Teel, Ph.D., Chief Business Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events and Presentations section of the Company’s website.
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.comand connect on LinkedIn and X.
Jeff.Boyle@arvinas.com
Kirsten.Owens@arvinas.com

Tags

targeted protein degradation

Frequently Asked Questions

What type of company is Arvinas, Inc.?

Arvinas, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation.

When will Arvinas participate in the Leerink Partners conference?

Arvinas will participate in the Leerink Partners Global Healthcare Conference on March 11.

What is the main focus of Arvinas's drug development?

Arvinas focuses on developing therapies that degrade disease-causing proteins using its PROTAC platform.

Who will represent Arvinas at the investor conferences?

Andrew Saik and Randy Teel, Ph.D., will represent Arvinas at the upcoming investor conferences.

Tags: ARVN Viatris Investor Conferences Healthcare investor conference biotechnology healthcare clinical development
Last updated: Mar 4, 2025